Trial Profile

An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined with JAB-3312 Compared Tislelizumab Combined with Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer with KRAS P.G12C Mutation

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glecirasib (Primary) ; Sitneprotafib (Primary) ; Carboplatin; Pemetrexed; Tislelizumab
Indications Non-small cell lung cancer
Focus Registrational; Therapeutic Use
Sponsors Allist Pharmaceuticals

02 Sep 2024 Status changed from not yet recruiting to recruiting.
02 Jun 2024 According to Jacobio Pharmaceuticals media release, phase III study in combination with KRAS G12C inhibitor Glecirasib has been approved by China CDE in Feb 2024.
14 May 2024 Status changed from planning to not yet recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com